Innate Pharma Notes AstraZeneca’s Updated Timing For PACIFIC-9 Phase 3 NSCLC Trial Readout: First Half 2027, Not Second Half 2026; Enrollment Complete
Share
Why It Matters
A big medicine test got pushed back by several months. When companies delay results, watch to see if they explain why clearly.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.